Bronchoscopic Lung Ablation of Small Thoracic Tumors: the Blastt Registry

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06840288

Enrollment

250

Registered

2025-02-21

Start date

2025-02-19

Completion date

2036-12-31

Last updated

2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic Tumors

Brief summary

To aggregate, integrate, and analyze data facilitating the study of MD Anderson patients with a known diagnosis of lung cancer or metastases to the lungs who undergo robotic assisted bronchoscopic ablation of peripheral tumors.

Detailed description

A. To aggregate, integrate, and analyze data facilitating the study of MD Anderson participants with a known diagnosis of lung cancer or metastases to the lungs who undergo robotic assisted bronchoscopic ablation of peripheral tumors. B. To assess the intra-operative, peri-operative, and long-term safety outcomes of robotic assisted bronchoscopic ablation of peripheral lung tumors. C. To evaluate different oncologic outcomes including local tumor progression (LTP) by RECIST criteria, local tumor progression free survival (LTPFS), progression free-survival (PFS), disease (cancer) specific survival (DSS), and overall survival (OS). D. To provide a deeper understanding of the evolution of radiographic findings of bronchoscopically ablated lung tumors over time. E. To evaluate tumor and participant-related risk factors that may be associated with safety (bleeding, pneumothorax, and local infection) and oncologic outcomes (LTPFS, PFS, DSS, and OS).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

Patients with peripheral lung tumors (primary or metastatic) that have been or will be ablated via robotic bronchoscopy.

Exclusion criteria

Patients with planned bronchoscopic ablations of peripheral lung tumors that were aborted for technical reasons (ablation was not completed).

Design outcomes

Primary

Measure	Time frame
To aggregate, integrate, and analyze data facilitating the study of MD Anderson patients with a known diagnosis of lung cancer or metastases to the lungs who undergo robotic assisted bronchoscopic ablation of peripheral tumors.	Through study completion, an average of 1 year.

Countries

United States

Contacts

CONTACTRoberto F Casal, MD

rfcasal@mdanderson.org(713) 792-6238

PRINCIPAL_INVESTIGATORRoberto F Casal, MD

Prinicipal Investigator

Outcome results